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Atopic diseases, including asthma, atopic der-
matitis (AD), and allergic rhinitis, are associated 
with a genetic predisposition to develop pro-
infl  ammatory immune responses to harmless 
components of the environment. These aber-
rant immune responses are characterized by the 
development of CD4+ T lymphocytes produc-
ing Th2 cytokines (IL-4, IL-5, and IL-13) and 
inducing the production of IgE antibodies. The 
important roles of Th2 lymphocytes and IgE-
dependent activation of tissue mast cells (MCs) 
in acute and chronic infl  ammation characteriz-
ing atopic diseases have been well established in 
clinical and animal models. The allergic infl  am-
mation involves the accumulation of a cellular 
infi  ltrate in the airway mucosa or the skin con-
sisting of eosinophils, CD4+ T cells, MCs, 
DCs, and basophils (1, 2).
Compelling evidence was recently provided 
that thymic stromal lymphopoietin (TSLP), an 
epithelial cell–derived cytokine, may have a 
determinant role in the initiation and mainte-
nance of the allergic immune response (3, 4). 
TSLP was initially shown to activate and 
instruct human CD11c+ DCs to promote the 
diff  erentiation of naive CD4+ T cells into Th2 
proinfl  ammatory eff  ectors, defi  ned by the pro-
duction of high levels of pro-allergic cytokines 
IL-4, IL-5, IL-13, TNF, and low levels of IL-
10 (5, 6). The role of TSLP in allergic diseases 
was subsequently supported by the fi  ndings 
that it was specifi   cally overexpressed in the 
acute and chronic lesions of AD patients and 
in the bronchi of asthmatic patients, where its 
level of expression correlated with the sever-
ity of the disease (3, 7). The ability of TSLP 
to act as the initiating cytokine at the top of a 
chain of immunological events that lead to the 
atopic syndrome was formally demonstrated 
in animal models (8–10). Overexpression of 
the TSLP gene specifi  cally in airway epithelial 
cells or keratinocytes led to asthma- and AD-
like diseases, respectively (9, 10). Moreover, 
increased expression of TSLP in the keratino-
cytes of mice genetically defi  cient in retinoic 
acid receptor or treated by topical application 
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of vitamin D3 was correlated with the occurrence of typi-
cal immunological and histological features of AD (11, 12). 
However, the fi  ndings that induction of experimental der-
matitis or asthma can occur in TSLP-transgenic mice lacking 
T cells (TCRβ−/− or RAG−/−) demonstrated that bronchial 
or cutaneous allergic diseases can occur in T cell– and IgE-
defi  cient animals (9–11). These fi  ndings suggested to us that 
TSLP may directly activate eff   ector cells of the innate 
immune system like MCs, which are known to play an impor-
tant role in the pathogenesis of atopic diseases (13, 14). Here, 
we report that TSLP released by primary epithelial cells in 
response to clinically relevant stimuli directly activates hu-
man MCs inducing the production of high levels of Th2 pro-
infl  ammatory cytokines.
RESULTS AND DISCUSSION
Human MCs express functional receptor for TSLP
The expression of each chain of TSLP receptor complex, i.e., 
the TSLP-binding chain (TSLP-R) and the IL-7Rα chain 
(15), was fi  rst examined on progenitor-derived MCs at the 
mRNA and protein levels. TSLP-R mRNA was expressed 
on MCs but not on T cells used as a control. IL-7Rα was ex-
pressed at lower levels on MCs than on T cells. Expression of 
TSLP receptor complex was indicated by double labeling 
with mAb to c-kit in tandem with mAbs to either TSLP-R 
or IL-7Rα (Fig. 1 A). Importantly, TSLP receptor was also 
expressed in vivo on MCs infi  ltrating the bronchial mucosa 
of asthmatic patients as revealed by immunostaining of biopsy 
specimen (Fig. 1 B). Initial observations revealed that only 
IL-1 but not TNF, IL-4, or IL-6 exerted a permissive eff  ect 
on the activation of MCs by TSLP as illustrated by the pro-
duction of IL-5 (Fig. 1 C). Moreover, the response to TSLP 
plus IL-1 was further enhanced by TNF but not by IL-4 or 
IL-6. All the in vitro–generated MC lines examined in this 
study (n = 19) responded to TSLP in the presence of IL-1/
TNF, regardless of whether they were derived from the 
blood of atopic or nonatopic adults or umbilical cord blood. 
The response of MCs to TSLP was dose dependent (Fig. 1 D); 
it was already detectable after 6 h of culture and reached pla-
teau at 24 h (Fig. 1 E). This response was TSLP specifi  c and 
mediated by TSLP-R. Indeed, (a) it was specifi  cally sup-
pressed by neutralizing mAb to TSLP or TSLP-R (Fig. 1, 
F and G), and (b) the inhibitory activities of these mAbs were 
TSLP specifi  c in that they had no eff  ect on the production 
of CCL2, which was highly induced by stimulation with 
IL-1/TNF in the absence of TSLP (Fig. S1 A, available at 
http://www.jem.org/cgi/content/full/jem.20062211/DC1).
TSLP stimulation of MCs induces cytokine production 
but not mediator release
Typically, IgE-dependent MC activation results in the libera-
tion of granule-associated mediators such as histamine and 
tryptase, the synthesis of lipid mediators such as PGD2 and 
LTC4, and the synthesis of a wide spectrum of cytokines 
and chemokines. MC activation is not a “yes or no” pheno-
menon, and similar to several other MC activators (for review 
see reference 16), TSLP did not induce MC degranulation 
or the release of lipid mediators (Fig. S2, available at 
http://www.jem.org/cgi/content/full/jem.20062211/DC1), 
even when used at various concentrations with or without 
IL-1/TNF. In contrast, very high levels of the proinfl  ammatory 
cytokines/chemokines IL-5, IL-13, IL-6, GM-CSF, CXCL8, 
and CCL1 were released after 24 h of MC stimulation by TSLP 
in the presence of IL-1/TNF (Fig. 2). Regardless of the ex-
perimental conditions, the following cytokines/chemokines, 
Figure 1.  Human MCs expressed functional receptor for TSLP. 
(A) TSLP-R and IL-7Rα chain expression was determined at mRNA on MCs 
and peripheral blood T cells (mean ± SEM of eight experiments on differ-
ent MC lines) and protein levels. (B) Tissue sections from the bronchial 
mucosa of asthmatic patients were stained with TSLP-R mAb using an 
HRP system (brown) and Astra Blue (blue) for the identifi  cation of MCs. 
(C) MCs were stimulated with TSLP alone or together with different in-
fl  ammatory cytokines. The 24-h culture supernatants were tested for their 
content in IL-5. One representative of three experiments is shown; mean ± 
SD of triplicates. (D) MCs were stimulated with varying concentrations of 
TSLP in the presence of 10 ng/ml IL-1 and 25 ng/ml TNF. One representa-
tive of three experiments is shown; mean ± SD of triplicates. (E) Time 
course of cytokine production by MCs stimulated with 10 ng/ml IL-1β/
TNF and TSLP. Mean ± SEM (n = 5). (F and G) MCs were stimulated in the 
presence of neutralizing mAb to TSLP (F) or TSLP-R (G) and isotype control 
IgG (each at 10 μg/ml). One representative of three experiments is shown; 
mean ± SD of triplicates.JEM VOL. 204, February 19, 2007  255
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including IL-4, IL-9, IL-12, IL-15, IFN-γ, CXCL10, 
CCL24, CCL17, CCL13, CCL22, and CCL5, were either 
undetectable or present at very low levels (<70 pg/ml). 
Stimulation of MCs with IL-1/TNF induced the release of 
high levels of CCL2 and CCL3, and this was not aff  ected by 
TSLP (CCL2: 3,512 ± 346 pg/ml vs. 3,912 ± 669 pg/ml 
with TSLP; CCL3: 3,921 ± 725 pg/ml vs. 3,415 ± 483 pg/ml 
with TSLP). Collectively, these data indicated that in in-
fl  ammatory conditions mimicked by the presence of IL-1 
and TNF, TSLP is a potent activator of MCs leading to the 
production of very high levels of proinfl  ammatory  Th2 
cytokines and chemokines that are reportedly suffi   cient to 
induce and maintain an allergic phenotype. For instance, the 
perfusion of IL-13 induces an asthma-like phenotype charac-
terized by eosinophilic infl  ammation, bronchial hyperreac-
tivity, and airway remodeling (17). Given the important role 
of TNF in severe asthma (18), it is of note that this cytokine 
was released at high levels by MCs stimulated with IL-1 and 
TSLP (not depicted). The proinfl  ammatory activity of TSLP 
was further indicated by its suppressive activity on the pro-
duction of TGF-β. This fi  nding together with the observa-
tion that TGF-β inhibits the response to TSLP (Fig. S3) 
suggests a negative regulatory feedback between these two 
cytokines. In contrast to TGF-β, the production of IL-10 
was enhanced by TSLP and exogenous IL-10 did not aff  ect 
the MC response to TSLP (not depicted). IL-10 is overex-
pressed in the lesional skin of AD patients (19) where it in-
hibits the production of antimicrobial peptides, thereby 
contributing to the microbial colonization of the skin (20). 
Because IgE/anti-IgE–stimulated MCs reportedly expressed 
TSLP mRNA (5), we have examined TSLP expression in 
response to IL-1/TNF used alone or together with exoge-
nous TSLP. TSLP was not induced in these conditions as re-
vealed by: (a) the absence of TSLP protein in the culture 
supernatants of IL-1/TNF-stimulated MCs (<7 pg/ml), 
(b) the lack of eff  ect of blocking anti-TSLP mAb on chemo-
kine production by IL-1/TNF-stimulated MCs, and (c) 
quantitative real-time RT-PCR analysis of TSLP mRNA 
expression (Fig. S1, A and B). The potential clinical signifi  -
cance of the fi  ndings that TSLP-stimulated MCs produce 
high levels of proinfl  ammatory Th2 cytokines and chemo-
kines is supported by the recently reemphasized concept that 
MCs have a central role in the development and maintenance 
of allergic diseases (for review see reference 13).
Human epithelial cells produce biologically active TSLP
Given that overexpression of TSLP in the airway epithelial 
cells induces experimental asthma (9), and that TSLP mRNA 
is overexpressed in the bronchial mucosa of asthmatic pa-
tients (7), we attempted to identify stimuli capable of induc-
ing TSLP production by human airway epithelial cells. To 
this end, primary small airway epithelial cells (SAECs) were 
stimulated with: (a) a cocktail of IL-1 and TNF to mimic 
the infl  ammatory microenvironment, and (b) bacterial pep-
tidoglycan (PGN) and TLR ligands such as lipoteichoic acid 
(LTA) from Bacillus subtilis, poly I:C (mimicking viral double-
stranded RNA), LPS, imiquimod, and CpG. TSLP was pro-
duced only in response to the infl  ammatory cytokines, PGN, 
LTA, and poly I:C (Fig. 3 A and Fig. S4, which is available at 
http://www.jem.org/cgi/content/full/jem.20062211/DC1). 
The failure of SAEC to respond to LPS, imiquimod, and 
CpG was explained by the lack of expression of the corre-
sponding TLR’s mRNA (Fig. 3 B). The supernatant fl  uids 
of activated SAECs promoted the TSLP-dependent pro-
liferation of a BAF cell line transfected with the human TSLP 
receptor complex (Fig. 3 C). Moreover, the low levels of 
TSLP present in these culture supernatants were suffi   cient 
when used together with IL-1/TNF to induce IL-13 and 
IL-5 production from MCs (Fig. 3, D–F, and not depicted). 
Native SAEC-derived TSLP was active at much lower con-
centrations (50–100 pg/ml; see Fig. 3 A) than recombinant 
TSLP (10 ng/ml) used as a positive control (Fig. 3 D). This 
fi  nding suggested that activated SAECs may produce addi-
tional factors that act to co-stimulate the response of MCs 
to TSLP; alternatively, it could refl  ect a diff  erence in the 
Figure 2.  TSLP-stimulated secretion of cytokines and chemokines 
by MCs. Cytokine (A) and chemokine (B) secretion by MCs (105 cells/ml) 
stimulated for 24 h with 10 ng/ml IL-1β/TNF or/and TSLP was assessed by 
ELISA. Mean ± SEM (n = 11).256  EPITHELIAL CELL–DERIVED TSLP ACTIVATES MAST CELLS | Allakhverdi et al.
intrinsic activity of native and recombinant TSLP. It is of note 
that SAECs stimulated with cytokines, PGN, or polyI:C did 
not produce detectable IL-5 or IL-13. Moreover, PGN or 
polyI:C induced the production of very low (<70 pg/ml) 
or undetectable levels of IL-5 or IL-13 by MCs, even when 
used together with IL-1/TNF. The observation that bacterial 
and viral products induce TSLP production by SAEC may be 
related to the well-documented aggravating role of infection 
in allergic as well as intrinsic bronchial asthma. For exam-
ple, 60–80% of asthma exacerbations in children and adults 
are caused by rhinovirus infection (21). Rhinoviruses, like 
several other single-stranded RNA viruses, synthesize double-
stranded RNA during their replication, thereby engaging 
TLR3 and initiating signaling cascades leading to cytokine 
production (22). The up-regulation of TSLP by bacterial 
products is, however, not restricted to airway epithelial cells 
as it has been shown in intestinal epithelial cells (23). TSLP 
activation of MCs may also contribute to the aggravation of 
AD resulting from skin colonization by Staphylococcus aureus 
(1). Thus, certain bacterial, viral, and nonspecifi  c infl  amma-
tory stimuli (IL-1/TNF) may activate airway epithelial cells 
to produce TSLP in suffi   cient amounts to stimulate MCs and 
thereby initiate and/or aggravate allergic infl  ammation.
MC activation by skin-derived TSLP
Because TSLP protein is reportedly overexpressed at the le-
sional sites of AD (3), we examined the possible involvement 
of TSLP-induced MC activation in this disease. To this end, 
biopsy fragments of lesional and nonlesional skin from AD 
patients were examined for their ability to directly stimulate 
MCs in co-culture experiments. As seen in Fig. 4 A, lesional skin 
induced IL-13 production by MCs in a TSLP-dependent 
manner, whereas nonlesional skin from the same patients 
was less active. Moreover, TSLP mRNA levels were higher 
in biopsy fragments from lesional than nonlesional skin 
(Fig. 4 B). The fi  nding that nonlesional skin was active on 
MCs led us to test whether TSLP production was a feature of 
atopy or was induced by the physical trauma of the skin re-
sulting from the biopsy. The latter possibility was supported 
by the fi  nding that skin fragments of normal individuals re-
leased TSLP protein after 24 h of culture in suffi   cient quan-
tities to stimulate MCs (Fig. 4 C). No such activity was 
elicited by supernatant fl  uids collected after 1 h of skin cul-
ture. Because normal skin reportedly does not express detect-
able TSLP protein (3), the data suggest that TSLP was induced 
during the culture of skin explants. This view was supported 
by the fi  nding of increasing TSLP mRNA and protein ex-
pression over time in the skin cultures (Fig. 4, D and E). A 
similar result was obtained in experiments examining TSLP 
mRNA and protein expression over time in mouse skin 
punch biopsies (not depicted). The production of TSLP to-
gether with several proinfl  ammatory cytokines after physical 
trauma may account for the aggravating role of scratching in 
atopic eczema (1).
An emerging hypothesis regarding asthma and AD is that 
they are epithelial cell diseases initiated by the epithelial cells 
themselves via the production of TSLP (3). In the present 
study we have identifi  ed several clinically relevant stimuli 
leading to TSLP production by primary human airway and 
skin epithelial cells. We have further shown that these stimu-
lated epithelial cells release TSLP in suffi   cient amounts to 
activate, in synergy with IL-1/TNF, MCs to produce high 
levels of Th2 cytokines. These fi  ndings provide a possible 
mechanism to account for the induction of atopic-like dis-
eases in T cell– and IgE-defi  cient mice expressing a TSLP 
transgene or submitted to topical application of vitamin 
D3 on the skin (9, 11). Direct epithelial cell–mediated and 
TSLP-dependent activation of MCs may be implicated in 
the initiation and perpetuation of so-called “intrinsic” asthma 
or eczema in  20–30% of patients (24). Such patients have 
normal serum IgE concentration and negative skin prick test 
Figure 3.  Induction of TSLP production by primary human airway 
epithelial cells. (A) SAECs were stimulated as indicated, and the 48-h 
culture supernatants were tested for their content in TSLP by ELISA. Mean ± 
SEM (n = 5). (B) Expression of the indicated TLR mRNA in SAECs was 
determined by real-time PCR. (C) BAF cells (104 cells/well) expressing the 
human TSLP-R and IL-7Rα chains were cultured in the presence of SAEC 
supernatants and in the presence or absence of neutralizing anti-TSLP 
mAb, and their proliferation was assessed after 3 d. One representative of 
three experiments is shown; mean ± SD of triplicates. (D–F) MCs were 
cultured in the presence or absence of supernatants of SAECs (50% vol/
vol) described in A that were obtained upon stimulation with IL-1α/TNF 
(D), PGN (E), or polyI:C (F). IL-13 and IL-5 (not depicted) were measured 
after 24 h of MC stimulation. Mean ± SEM of four to fi  ve experiments.JEM VOL. 204, February 19, 2007  257
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toward allergens; however, their infl   ammatory lesions are 
indistinguishable from those observed in patients with clas-
sical IgE-dependent “extrinsic” forms of the diseases (25). 
The same mechanism may also explain why in infants the 
eczematous skin lesions often start in the absence of specifi  c 
IgE antibodies, implicating that IgE sensitization may occur 
after the eczema (24).
Together with earlier studies, the present data may be 
taken to suggest that TSLP induces and/or perpetuates aller-
gic diseases by acting on the two main sentinels of the innate 
immune system, i.e., DCs and MCs colocalized at the epithe-
lial surfaces.
MATERIALS AND METHODS
MC cultures. All studies were approved by the ethics committee of CHUM 
Research Center. Human peripheral blood– or cord blood–derived CD34+ 
progenitor cells were isolated and cultured as described previously (26). After 
10–12 wk of culture, >98% of cells were stained for c-kit (Becton Dickinson), 
FcεRI (eBioscience), and tryptase (Chemicon). 2 × 104/0.2 ml MCs were 
cultured in 96-well fl  at-bottom plates for 24 h in the presence of exogenous 
cytokines/neutralizing antibodies as indicated. The antibodies used include: 
anti–IL-7Rα (R&D Systems); anti–TSLP-R (M505; Amgen); anti-TSLP 
(M385; Amgen); anti–IL-10 (American Type Culture Collection). Recom-
binant cytokines included: IL-1β, TNF (R&D Systems), and recombinant 
TSLP (Amgen).
Assessment of mediator, 𝗃-hexosaminidase, cytokine, and chemo-
kine release. MCs were incubated for 30 min for histamine and 90 min for 
PGD2 and LTC4, as well as release with cytokines or PMA/ionomycin as a 
positive control, and ELISA was performed (Immunotech and Cayman 
Chemical) according to the manufacturers’ instructions. β-Hexosaminidase 
release was analyzed as described previously (27). IL-4, IL-5, IL-6, CXCL8, 
IL-9, IL-10, IL-12, IL-13, IL-15, CCL24, CCL1, IFN-γ, CXCL10, GM-
CSF, CCL22, CCL3, CCL2, CCL13, CCL5, CCL17, and TGF-β were 
examined in supernatants harvested after 24 h of MC activation via com-
mercial kits. All assays were conducted in triplicates.
Real-time quantitative PCR. RNA was isolated with RNeasy Mini kit 
(QIAGEN). cDNA synthesis was performed using ABI fi  rst strand cDNA 
synthesis kit. Quantitative real-time PCR was performed via a TaqMan using 
ABI gene expression assays. HPRT was used as a control for cDNA input.
Activation of primary SAECs. Primary SAECs (Clonetics) were grown 
to confl  uence and stimulated in the presence of 25 ng/ml TNF/10 ng/ml 
IL-1α, 100 μg/ml PGN from S. aureus, LTA from 2 μg/ml B. subtilis, 
50 μg/ml polyI:C, 1 μg/ml LPS, 10 μg/ml imiquimod, or 5 μM CpG.
Proliferation assay. BAF cells stably expressing the human TSLP-R and 
IL-7Rα chains were cultured with SAEC supernatants in the presence or 
absence of neutralizing anti-TSLP antibody for 3 d, and proliferation was as-
sessed by CyQUANT Cell Proliferation Assay kit (Invitrogen) according to 
the manufacturer’s instructions.
MCs and skin explant co-cultures. MCs were directly co-cultured with 
lesional and nonlesional skin fragments from AD patients for 24 h in the 
presence or absence of exogenous cytokines/neutralizing antibodies as indi-
cated. Supernatants of skin explants from normal individuals undergoing 
plastic surgery were added to MCs in the presence or absence of exogenous 
cytokines/neutralizing antibodies as indicated.
Statistical analysis. Student’s paired t test and ANOVA (Tukey-Kramer 
Multiple Comparisons test) were used to determine the statistical signifi  -
cance of the data.
Online supplemental material. Fig. S1 shows the lack of eff  ect of anti-
TSLP mAb on MC response to cytokines and on expression of TSLP mRNA. 
Figure 4.  MC activation by skin-derived TSLP. (A) MCs were cultured 
with or without lesional or nonlesional skin fragments from AD patients in 
the presence of IL-1β/TNF with or without neutralizing mAb to TSLP. IL-13 
and IL-5 (not depicted) were measured in the supernatants after 24 h of 
culture. (B) TSLP mRNA was assessed in the lesional and nonlesional skin of 
AD patients by real-time PCR. (C) Skin explants from nonallergic patients 
undergoing plastic surgery were minced and cultured for 24 h. Their cell-
free culture supernatants (50% vol/vol) were used to stimulate MCs in the 
presence of IL-1β/TNF with or without mAb to TSLP and TSLP-R or isotype 
control. IL-13 was measured after 24 h of culture. One representative of 
three experiments is shown; mean ± SD of triplicates. (D) TSLP mRNA was 
assessed on freshly isolated or cultured for 24-h skin explants. (E) TSLP 
protein was measured in the supernatant fl  uids of these cultures. One 
representative of three experiments is shown; mean ± SD of triplicates.258  EPITHELIAL CELL–DERIVED TSLP ACTIVATES MAST CELLS | Allakhverdi et al.
Fig. S2 illustrates the failure of TSLP to stimulate MC degranulation and 
eicosanoid production. Fig. S3 illustrates the suppressive eff  ect of TGF-β 
on TSLP response, and Fig. S4 shows the induction of TSLP production by 
SAECs in response to specifi  c TLR2 ligand. The online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20062211/DC1.
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